In the context of human malignancies, analysis of 5989 patient samples of haematopoietic cancers using the cBioPortal database showed no correlation between ARRDC3 mutation (loss/amplification) with either MYC amplification or TP53 loss [50–52]. This evidence concerns the gene ARRDC3 and hematopoietic and lymphoid cell neoplasm.